.png)
.png)
Latest news from BIA
BIA welcomes legal confirmation that discoveries made through “routine” research can be patentable in ICOS vs Actavis ruling
In a ruling handed down today (27 March) by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be inventive and rewarded with a patent
Investors maintain confidence in UK biotech at start of 2019
New figures published today (Monday 25 March 2019) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence shows a strong start to 2019 for venture capital investment in UK biotech.
BIA welcomes Minister’s Reassurance on the Patents (Amendment) (EU Exit) Regulations 2018
The Government last night committed to further consultation with the BIA on the UK’s future Intellectual Property rights regime in the event of a ‘no deal’ Brexit following concerns raised in the House of Lords.
2018 a record year for UK biotech fundraising
New figures published today (Thursday 24 January 2019) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised a record £2.2 billion from investors in 2018. The total is the best ever recorded by the trade association and almost double that raised in 2017. The data is presented in the report Confident capital: backing UK biotech and launched by the Exchequer Secretary to the Treasury, Robert Jenrick MP, at the BIA's Strategic Technologies event in central London today.
Congenica Co-founder and Scientific Director Dr Matthew Hurles Elected to Fellowship of the Royal Society
Cambridge, United Kingdom – 18 April, 2019 - Congenica, the global diagnostic decision support platform provider, congratulates its co-founder and Scientific Director, Dr Matthew Hurles, FMedSci FRS, who has been elected to Fellowship of the Royal Society, the UK’s most prestigious scientific organisation.
BioDivide Ltd Announces the Launch of the Next Generation Equine Stem Cell Therapy
BioDivide has developed a new stem cell technology for horses called StemPlan. The launch of StemPlan will be supported by a series of CPD events to provide veterinarians with the most up-to-date information about equine regenerative medicine.
Coulter Partners places Chairman and Chief Executive Officer for OxStem
Coulter Partners was very pleased to partner with OxStem Limited, a leading biotechnology company focussed on regenerative medicine, to secure the appointment of Dr Stuart Collinson as Chairman and Chief Executive Officer.
Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer
Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual circumstances of patients.
Video of the Week | National Apprenticeship Week 2019 | Advanced Therapies
During National Apprenticeship Week apprentices and participating employers gathered at Oxford BioMedica to discuss how the first of its kind advanced therapies apprenticeship programme is key to meeting the industry demands for advanced therapies. Dr Ian Campbell, interim Executive Chair, Innovate UK, delivered the keynote speech and highlighted the Government’s commitment to the programme. Other highlights of the day included a Q&A session with current apprentices and the launch of three new programmes in regulatory affairs, senior management and the Scottish modern apprenticeship in life sciences.
CEO Update | Monday 15 April 2019
Easter is fast approaching, Parliament has risen for a two week recess and MPs have left Westminster to contemplate their next steps after yet another dramatic Brexit week.
Video of the week | Benevolent AI and Parkinson's UK
It's been 50 years since a new treatment for Parkinson's has been discovered. Current treatments focus on treating the motor symptoms of Parkinson's, and come with a whole host of often debilitating side effects. This video forms part of a BIA campaign called Celebrating UK Bioscience, and explores a project between BIA Charity of the year 2018, Parkinson's UK, and BIA member Benevolent AI. Harnessing the power of AI, they hope to identify new targets for drugs, and molecules which may have failed in their particular indication of study, but could be repurposed to help fight Parkinson's. Check out this video #WorldParkinsonsAwarenessWeek
CEO Update | Monday 8 April 2019
With impeccable timing, we’ve got our next members’ Brexit webinar this Friday – the day of the next possible Brexit no-deal deadline. I expect that lots will change between now and then; we'll update you on what it all means for our sector. Wish us luck! The Conservative/Labour Brexit talks continue today, in the run up to the European Council on Wednesday. There, European leaders will discuss the Prime Minister’s request for an Article 50 extension to 30 June – which requires the agreement of all 27 EU members. At the same time the UK Parliament ‘taking back control’ continues, with Yvette Cooper’s European Union (Withdrawal) (No 5) Bill in the House of Lords today and returning to the House of Commons later this week.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
